Autoantibodies against p53 protein in patients with transitional cell carcinoma of the bladder

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3531-3537

  Sanchez Carbayo, Marta ^a   Chulia, Maria Teresa ^b   Niveiro, Maria ^b   Aranda, Ignacio ^b   Mira, Antonio ^b   Soria, Federico ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NONE

Author keywords

Antip53 auto antibodies; Bladder cancer; Diagnosis; P53 suppressor gene; Tumor marker

Indexed keywords

AUTOANTIBODY; MUTANT PROTEIN; PROTEIN P53;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AUTOANTIBODIES; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0033428483     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Raghaven D, Shipley WU, Garnick MB, Russell PJ, and Richie JP: Biology and management of bladder cancer. New Engl J Med 322: 1129-1138, 1990.
2. Newling DW: Preventing recurrence and progression in superficial bladder cancer. Current opinion in Urology 6: 272-279, 1996.
3. Foresman WH and Messing EM: Bladder cancer: natural history, tumor markers and early detection strategies. Semin Surg Oncol 13 (5): 294-306, 1997.
4. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DA, Cote RJ: Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160: 645-59, 1998.
5. Cordon- Cardo C, Sheinfeld J, Dalbagni G: Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 13: 319-27, 1997.
6. Cordon-Cardo C, Reuter VE: Alterations of tumor suppressor genes in bladder cancer. Semin Diagn Pathol 14: 1223-32, 1997.
7. Levine AJ, Momand J and Finlay A: The p53 tumor suppressor gene. Nature 351: 49-53, 1991.
8. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
9. Harris CC and Hollstein M: Clinical implications of the p53 tumor suppressor gene. New Engl J Med 329: 1318-1327, 1993.
10. Cordon Cardo C, Dalbagni D, Saez GT, Oliva MR, Zhang J Rosai Z-F, Reuter VE and Pellicer A: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347-352, 1994.
11. Esrig D, III Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen S-C, Skinner DG, Jones PA and Cote RJ: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Amer J Path 143: 1389-1394, 1993.
12. Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentni RR, Lane DP: Absence of p53 auto-antibodies in a significant proportion of breast cancer patients. Br J Cancer 71: 1253-6, 1995.
13. Willsher PC, Pindre SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blarney RW, Green JA, Robertson JF: The significance of p53 auto-antibodies in the serum of patients with breast cancer. Anticancer Res 16: 927-30, 1996.
14. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DB: Development of antibodies against p53 in lung cancer patients appear to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
15. Wurl P, Weigmann F, Meye A, Fittkau M, Rose U, Berger D, Rath FW, Dralle H, Taubert H. Detection of p53 auto-antibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol 32(11): 1147-1151, 1997.
16. Gansauge S, Gansauge F, Negri G, Galle P, Muller J, Nussler AK, Poch B, Beger HG: The role of anti-p53-auto- antibodies in pancreatic disorders. Int J Pancreatol 19: 171-8, 1996.
17. Sthoeger Z, Evron E, Goland S, Shani A, Wolkowicz R, Goldfinger N, Rotter V, Fogel M. Anti- p53 auto- antibodies in colon cancer patients. Ann N Y Acad Sci 815: 496-8, 1997.
18. Raedle J, Oremek G, Truschnowitsch M, Lorenz M, Roth WK, Caspary WF, Zeuzem S: Clinical evaluation of auto- antibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Eur J Cancer 34 (18): 1198-203, 1948.
19. Wollenberg B, Jan NV, Pitzke P, Reiter W, Stieber P. Anti-p53 antibodies in serum of smokers and head and neck cancer patients. Anticancer Res 17: 413-418, 1997.
20. Angelopoulo K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 78: 2146-52, 1997.
21. Schmitz-Drager BJ, Kushima M, Goebell P, Jax TW, Gerhard CD, Bultel H, Schultz WA, Ebert T, Ackermann R. P53 and MDM2 in the development and progression of bladder cancer. Eur Urol 32(6): 487-493, 1997.
22. Inagaki T, Ebisumo S, Uekado Y, Hirano A, Hiroi A, Shinka T, Ohkawa T. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis. Int J Urol 4(2): 172-177, 1997.
23. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA and Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. New Eng J Med 331: 1259-1265, 1994.
24. American Joint Committee on Cancer: Staging of cancer at genitourinary sites. In: American Joint Committee on Cancer: Manual for Staging of Cancer, 3rd Edition. Philadelphia: JB. Lippincott Co, pp 194-195, 1988.
25. Mostofi FK: Histological Typing of Urinary Bladder Tumors. Geneva: World Health Organization, 1973.
26. Labrecque S, Naor N, Thomson D and Mathalewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53: 3468-3471, 1993.
27. Raedle J, Oremek G, Roth WK, Caspary WF, Zeuzem S: Anti-p53 auto- antibodies in hepatitis C virus-infected patients. Anticancer Res 17: 3079-81, 1997.
28. Munker R, Stotzer, Darsow M, Classen S, Lebeau A, Wilmanns W: Auto- antibodies against p53 are not increased in human ascites and pleural effusions. Cancer Immunol Immunother 42: 200-1, 1996.